Novartis press release ( NVS ): Q4 Non-GAAP EPS of $2.03 beats by $0.03 . Revenue of $13.34B (+1.4% Y/Y) misses by $740M . Net sales -1% (cc, +1% USD), impacted by US generic erosion and revenue deduction adjustments; core operating income +1% (cc, +1% USD). Free cash flow amounted to USD 1.7 billion (-54%), driven by lower net cash flows from operating activities. Dividend of CHF 3.70 per share, ...
Novartis press release ( NVS ): Q4 Non-GAAP EPS of $2.03 beats by $0.03 . Revenue of $13.34B (+1.4% Y/Y) misses by $740M . Net sales -1% (cc, +1% USD), impacted by US generic erosion and revenue deduction adjustments; core operating income +1% (cc, +1% USD). Free cash flow amounted to USD 1.7 billion (-54%), driven by lower net cash flows from operating activities. Dividend of CHF 3.70 per share, an increase of 5.7%, proposed for 2025. 2026 guidance – Net sales expected to grow low single-digit and core operating income expected to decline low single-digit. "In 2026, we expect to grow through the largest patent expiry in Novartis history, underscoring the strength of our business, and remain well on track to deliver our mid-term guidance." More on Novartis Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade) Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Novartis Q4 2025 Earnings Preview SA analyst upgrades/downgrades: GM, UBER, UNH, NVS
Novartis press release ( NVS ): Q4 Non-GAAP EPS of $2.03 beats by $0.03 . Revenue of $13.34B (+1.4% Y/Y) misses by $740M . Net sales -1% (cc, +1% USD), impacted by US generic erosion and revenue deduction adjustments; core operating income +1% (cc, +1% USD). Free cash flow amounted to USD 1.7 billion (-54%), driven by lower net cash flows from operating activities. Dividend of CHF 3.70 per share, ...
Novartis press release ( NVS ): Q4 Non-GAAP EPS of $2.03 beats by $0.03 . Revenue of $13.34B (+1.4% Y/Y) misses by $740M . Net sales -1% (cc, +1% USD), impacted by US generic erosion and revenue deduction adjustments; core operating income +1% (cc, +1% USD). Free cash flow amounted to USD 1.7 billion (-54%), driven by lower net cash flows from operating activities. Dividend of CHF 3.70 per share, an increase of 5.7%, proposed for 2025. 2026 guidance – Net sales expected to grow low single-digit and core operating income expected to decline low single-digit. "In 2026, we expect to grow through the largest patent expiry in Novartis history, underscoring the strength of our business, and remain well on track to deliver our mid-term guidance." More on Novartis Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade) Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Novartis Q4 2025 Earnings Preview SA analyst upgrades/downgrades: GM, UBER, UNH, NVS
Key Points Software stocks continue to tumble on AI-driven fears. Investors seem to think Microsoft is overspending on capital expenditures. The stock is trading at a modest discount to the S&P 500. 10 stocks we like better than Microsoft › Nearly a week after software stocks plunged in response to earnings reports from industry heavyweights like Microsoft (NASDAQ: MSFT), ServiceNow, and SAP that ...
Key Points Software stocks continue to tumble on AI-driven fears. Investors seem to think Microsoft is overspending on capital expenditures. The stock is trading at a modest discount to the S&P 500. 10 stocks we like better than Microsoft › Nearly a week after software stocks plunged in response to earnings reports from industry heavyweights like Microsoft (NASDAQ: MSFT), ServiceNow, and SAP that were less than perfect, the sector continued to plumb new depths. The iShares Expanded Tech-Software ETF, which tracks the cloud software sector, fell more than 5% on Tuesday and is now down 13% since Jan. 28. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Investors seem to fear that AI could disrupt the cloud software sector, enabling companies to develop tools in-house that could replace many of the subscription software products they use today, or at least reduce their dependence on them. The software-as-a-service (SaaS) sector has also historically traded at a sky-high multiple, and investors have been willing to allow these companies to spend generously on share-based compensation, often reporting generally accepted accounting principles (GAAP) net losses. Today, many large, well-known software companies are still losing money on a GAAP basis. However, Microsoft isn't one of them. The tech giant, which is probably the most diversified of the "Magnificent Seven" companies, is now down 26% from its peak just three months ago. While the broader sell-off in subscription software stocks makes sense since many of these companies don't have real cash flows to fall back on if their growth potential evaporates, Microsoft still looks rock-solid. What the numbers say Microsoft's latest earnings report offered little reason to explain the stock's 25% plunge, which has wiped off $1 trillion in its market cap. Overall revenue jumped 17% to $81.3 billion, paced by 39% growth from Azure, and adjust...
In this article UBSG-CH Follow your favorite stocks CREATE FREE ACCOUNT Fabrice Coffrini | AFP | Getty Images UBS reported its fourth quarter results on Wednesday, with net profits beating analysts' forecasts. The Swiss banking giant's fourth-quarter results statement showed net profit attributable to shareholders came in at $1.2 billion in the final three months of the year. That was up on analys...
In this article UBSG-CH Follow your favorite stocks CREATE FREE ACCOUNT Fabrice Coffrini | AFP | Getty Images UBS reported its fourth quarter results on Wednesday, with net profits beating analysts' forecasts. The Swiss banking giant's fourth-quarter results statement showed net profit attributable to shareholders came in at $1.2 billion in the final three months of the year. That was up on analysts' estimated $919 million, and was a decrease from the previous quarter's net profit of $2.5 billion. Overall, its group revenues were $12.1 billion for the final quarter of the year, which was in line with the $12.1 billion forecast by analysts. It was also down from $12.8 billion in the previous quarter, and up from $11.6 billion for the same period a year ago. Stock Chart Icon Stock chart icon UBS. Meanwhile, UBS' common equity tier (CET) 1 capital ratio — a gauge of a bank's solvency — was 14.4 % for the fourth quarter, compared to 14.8% in the previous quarter. CEO Sergio Ermotti — who is preparing to step down from his role as head of Switzerland's largest lender in April next year once its absorption of Credit Suisse is concluded — said the bank made "great progress" on "one of the most complex integrations in banking history." Ermotti returned to the helm in 2023 to oversee the government-led emergency takeover of the UBS' stricken Swiss rival. This is a breaking news story. Please refresh for updates.
The person said the script created an alert for which employee names within a tool like the team communication platform Slack were being removed or deactivated, giving some insight into who at the company was impacted by the layoffs.
The person said the script created an alert for which employee names within a tool like the team communication platform Slack were being removed or deactivated, giving some insight into who at the company was impacted by the layoffs.
Credit Agricole SA fell short of analysts’ profit estimates for the fourth quarter as costs rose to revamp its Italian business and it set aside more money for souring loans and other risks. Operating expenses rose 4.7% to €4.1 billion, above the €3.9 billion analysts had expected, driven by restructuring expenses and the impact of a deposit guarantee fund in Italy. Provisions of €629 million also...
Credit Agricole SA fell short of analysts’ profit estimates for the fourth quarter as costs rose to revamp its Italian business and it set aside more money for souring loans and other risks. Operating expenses rose 4.7% to €4.1 billion, above the €3.9 billion analysts had expected, driven by restructuring expenses and the impact of a deposit guarantee fund in Italy. Provisions of €629 million also came in higher than expected, and included money set aside for legal risks from UK car loans and a recovery plan for Italian lender Banca Progetto. The accumulation of individual hits offset a strong performance at Credit Agricole’s asset gathering business, and underscores the challenges for Chief Executive Officer Olivier Gavalda as he emphasizes growth outside the French lender’s home market. Gavalda last year unveiled a new strategic plan that focuses on markets including Italy, where Credit Agricole is already the largest shareholder in Banco BPM SpA . Credit Agricole has raised its stake in the Italian peer to just above 20% amid a deal wave sweeping its second-largest market. The first consolidation of the stake reduced earnings in the fourth quarter by €607 million, though it should make a recurring contribution of around €100 million per quarter going forward. Revenue 6,996 7,092 -1.8% 6,777 Operating costs 4,100 3,917 4.7% 3,904 Cost of risk 629 594 5.9% 522 Net income 1,025 1,689 -39% 1,100 Asset gathering revenue 2,105 2,045 2.9% 1,969 Large customers revenue 2,152 2,108 2.1% 2,142 CET1 phased-in 11.8% 11.7% n/m 11.7% “We have very ambitious standalone goals for Credit Agricole Italia ,” Gavalda said on a call with reporters. “We will see in due course whether or not it is in our interest to increase our stake in Banco BPM,” he said in reply to questions, adding that “is not an issue for the Credit Agricole Group at present.” Both Gavalda and his counterpart at Banco BPM have signaled before that they could explore tie-up options between the Italian bank and Cr...
Tariq Ahmad, Head of APAC at Franklin Templeton, discusses growth opportunities for the asset manager in Japan and China. He also shares insights on how institutional investors are looking at de-dollarization. (Source: Bloomberg)
Tariq Ahmad, Head of APAC at Franklin Templeton, discusses growth opportunities for the asset manager in Japan and China. He also shares insights on how institutional investors are looking at de-dollarization. (Source: Bloomberg)
Earnings Call Insights: Mercury Systems, Inc. (MRCY) Q2 2026 Management View CEO William Ballhaus stated that "we delivered Q2 results that were ahead of our expectations with solid year-over-year growth in backlog, revenue and adjusted EBITDA, and robust free cash flow." He highlighted record first half revenue, a record backlog approaching $1.5 billion, and a 1.23 book-to-bill ratio. Ballhaus em...
Earnings Call Insights: Mercury Systems, Inc. (MRCY) Q2 2026 Management View CEO William Ballhaus stated that "we delivered Q2 results that were ahead of our expectations with solid year-over-year growth in backlog, revenue and adjusted EBITDA, and robust free cash flow." He highlighted record first half revenue, a record backlog approaching $1.5 billion, and a 1.23 book-to-bill ratio. Ballhaus emphasized four priorities: performance excellence, a thriving growth engine, expanding margins, and driving free cash flow. He described the acceleration of customer deliveries, resulting in approximately $30 million of revenue, $10 million of adjusted EBITDA, and $30 million of cash, primarily planned for the third quarter, being pulled forward into Q2. Ballhaus noted significant operational moves, including expanding manufacturing capacity in Phoenix, Arizona, with an additional 50,000 square feet of factory space to support ramp production for common processing architecture programs and efficient scaling for potential market tailwinds. He cited awards in priority sectors such as a scope expansion on a core missile defense program, key design wins in advanced air mobility and space-based applications, and follow-on production awards for U.S. missile franchises and international radar and electronic warfare applications. The quarter also included $20 million of follow-on awards leveraging common processing architecture and embedded cybersecurity software from the Star Lab acquisition. CFO David Farnsworth stated, "our second quarter results continue to reflect solid progress toward our goal of delivering organic growth, expanding margins and robust free cash flow." He provided details on the financials, noting bookings of $288 million, revenue of $233 million, adjusted EBITDA of $30 million, and free cash flow of $46 million. Farnsworth attributed operating expense decreases to efficiency improvements and headcount reductions, partially offset by restructuring charges and i...
UBS press release ( UBS ): Q4 GAAP EPS of $0.37 misses by $0.02 . Revenue of $12.15B (+4.4% Y/Y) beats by $130M . On an underlying basis, revenues increased by 10% to USD 12,199m. "As we approach the last mile of the integration, I am confident in our ability to capture the remaining synergies by the end of the year, which we increased by USD 0.5bn to USD 13.5bn. With Group invested assets exceedi...
UBS press release ( UBS ): Q4 GAAP EPS of $0.37 misses by $0.02 . Revenue of $12.15B (+4.4% Y/Y) beats by $130M . On an underlying basis, revenues increased by 10% to USD 12,199m. "As we approach the last mile of the integration, I am confident in our ability to capture the remaining synergies by the end of the year, which we increased by USD 0.5bn to USD 13.5bn. With Group invested assets exceeding USD 7 trillion for the first time and strong business momentum we are poised to achieve our 2026 exit rate targets and medium-term ambitions," said Sergio P. Ermotti, Group CEO. 4Q25 net profit up 56% YoY to USD 1.2bn. Return on CET1 capital (RoCET1) of 6.6% and underlying1 RoCET1 of 11.9%. Outlook: "In the first quarter, we expect a low single-digit percentage decline in Global Wealth Management’s net interest income, while in Personal & Corporate Banking NII is expected to remain broadly stable in US dollar terms. "We remain on track to complete the integration by the end of the year, and we are confident in our ability to achieve our financial targets." "On track to achieve 2026 exit-rate targets as we deliver on final stages of integration by year-end to capture synergies, notably executing on the remainder of the cost-saving program, including an additional USD 0.5bn identified across the Group." Maintaining attractive capital returns with a plan to propose a dividend of USD 1.10 per share at the upcoming AGM, up 22% YoY; plan to accrue for midteens percent increase in dividend per share in 2026; intend to repurchase USD 3bn of shares in 2026 with an aim to do more. Set 2028 ambitions with ~18% return on CET1 capital2 and ~67% cost/income ratio for the Group, driven by further sustainable growth and efficiency gains across our business divisions. More on UBS Group AG UBS Group AG (UBSS:CA) Presents at European Financials Conference 2025 Transcript UBS looking to sell AT1 bonds after reports about compromise plan on Swiss capital rules - report UBS may implement up t...
A woman in northwestern China forgot to turn off the tap of her water heater after bathing, causing an hours-long leak that turned her residential community into an outdoor skating rink. The woman, known as Wang, released a video on social media on January 16 apologising to residents in her neighbourhood in Lanzhou, Gansu province, the Xianfeng News reported. “I took a shower last night and then f...
A woman in northwestern China forgot to turn off the tap of her water heater after bathing, causing an hours-long leak that turned her residential community into an outdoor skating rink. The woman, known as Wang, released a video on social media on January 16 apologising to residents in her neighbourhood in Lanzhou, Gansu province, the Xianfeng News reported. “I took a shower last night and then forgot to turn off the water tap of my home’s solar water heater. The water was flowing out of the tank for nine hours,” she said in the clip. Wang, above, took a shower in the evening then forgot to turn off the water heater. Photo: Douyin “The skating rink in our community you saw this morning was made by me. I am sorry. I made this mistake,” added Wang. Advertisement The tank for her water heater is on the roof of the building. After Wang forgot to close the tap, the water kept flowing to the tank before leaking from it. Her rival video clip showed the water flowing out of the tank, streaming down the wall and spreading onto the road outside. Advertisement The night temperature in Lanzhou dropped to minus eight degrees Celsius in mid-January. The frozen road was first discovered by Wang’s father, who has a habit of getting up early every morning to work out.
Moves to ban under-16s from social media should raise deeper questions about who controls democracy’s digital infrastructure The last UK general election of the 20th century was also the first to anticipate, albeit faintly, the coming technological revolution. The 1997 Labour and Conservative manifestos both included pledges to connect schools to something they called “the information superhighway...
Moves to ban under-16s from social media should raise deeper questions about who controls democracy’s digital infrastructure The last UK general election of the 20th century was also the first to anticipate, albeit faintly, the coming technological revolution. The 1997 Labour and Conservative manifestos both included pledges to connect schools to something they called “the information superhighway”. That metaphor soon fell out of use, unmourned, although it contains an interesting policy implication. Roads need rules to prevent accidents. Superhighways do not sound like the kind of places where children should play. Rafael Behr is a Guardian columnist Guardian Newsroom: Can Labour come back from the brink? On Monday 30 April, ahead of May elections join Gaby Hinsliff, Zoe Williams, Polly Toynbee and Rafael Behr as they discuss how much of a threat is Labour from both the Green party and Reform and whether Keir Starmer can survive as leader of the Labour party? Book tickets here or at guardian.live Continue reading...
Paying attention to the calls of our avian neighbours can reduce stress, find scientists in Germany Feeling stressed? Try a dose of birdsong to lift the spirits. A new study shows that paying attention to the treetop melodies of our feathered friends can boost wellbeing and bring down stress levels. Previous research has shown that people feel better in bird-rich environments, but Christoph Randle...
Paying attention to the calls of our avian neighbours can reduce stress, find scientists in Germany Feeling stressed? Try a dose of birdsong to lift the spirits. A new study shows that paying attention to the treetop melodies of our feathered friends can boost wellbeing and bring down stress levels. Previous research has shown that people feel better in bird-rich environments, but Christoph Randler, from the University of Tübingen, and colleagues wanted to see if that warm fuzzy feeling translated into measurable physiological changes. They rigged up a park with loudspeakers playing the songs of rare birds and measured the blood pressure, heart rate and cortisol levels (a marker of stress) of volunteers before and after taking a 30-minute walk through the park. Some volunteers experienced the birdsong-enriched environment, some heard just natural birdsong, and some wore noise-cancelling headphones and heard no birdsong. Half of the recruits were asked to pay attention to the birdsong. Continue reading...
If you’re intimidated by making marmalade, the whole-fruit method is the perfect entry point. Blood oranges are simmered whole until soft, perfuming your home as they do so, then they’re sliced, skin and all, mixed with sugar and a fragrant cinnamon stick, and embellished with a shot of amaro. Squirrel the jars away for a grey morning, give a few to deserving friends, and be sure to keep at least ...
If you’re intimidated by making marmalade, the whole-fruit method is the perfect entry point. Blood oranges are simmered whole until soft, perfuming your home as they do so, then they’re sliced, skin and all, mixed with sugar and a fragrant cinnamon stick, and embellished with a shot of amaro. Squirrel the jars away for a grey morning, give a few to deserving friends, and be sure to keep at least one to make this elegant mocha marmalade mousse tart. A cocoa biscuit crust topped with a chocolate marmalade mousse and crowned with a cold brew coffee cream, it’s a delightful trifecta of bitterness that no one will ever guess is an easy no-bake dessert. No-bake mocha marmalade mousse tart (pictured top) If you’re not up for preserving, make this using shop-bought thick-cut marmalade. Prep 10 min Chill 10 hr Cook 1 hr Serves 8-10 For the topping 300g whipping cream 50g coffee beans 15g icing sugar A pinch of salt For the crust 230g digestive biscuits 15g cocoa powder, plus extra to finish, if you like 1 tbsp caster sugar, plus extra for rolling ½ tsp espresso powder ¼ tsp salt 115g unsalted butter, melted For the mousse 170g whipping cream 175g dark chocolate, roughly chopped 1 whole egg and 1 egg yolk ¼ tsp salt 120g blood orange marmalade with amaro and cinnamon (see recipe below ), or shop-bought thick-cut marmalade, plus extra to decorate 1 tbsp amaro Start the topping the night before. In an airtight container with a lid, mix the whipping cream and coffee beans, then cover and refrigerate overnight. If you like, you can also make the crust and mousse the night before to get ahead. Grease a 23cm springform tin and line the base and sides with baking paper. To make the crust, put the digestive biscuits, cocoa, sugar, espresso powder and salt in a food processor, then pulse until the biscuits are finely ground. Add the melted butter, pulse again until combined, then press the mix evenly into the base of the lined tin; refrigerate while you make the mousse. In a medium b...
February is the best month of the year to list your home for sale based on the likelihood of a seller successfully finding a buyer, according to research from Rightmove (RMV.L). The property platform's analysis, published on Wednesday, looked at millions of properties listed for sale between 2014 and 2024. However, it excluded 2020 from the analysis due to the pandemic, while 2025 was left out of ...
February is the best month of the year to list your home for sale based on the likelihood of a seller successfully finding a buyer, according to research from Rightmove (RMV.L). The property platform's analysis, published on Wednesday, looked at millions of properties listed for sale between 2014 and 2024. However, it excluded 2020 from the analysis due to the pandemic, while 2025 was left out of the research to account for homes that were listed later in year and may still be on the market. From this analysis, Rightmove found that an average 68.9% of homes listed for sale in February went on to successfully find a buyer. January, when activity starts to ramp back up after the Christmas period, and March, which Rightmove noted to be the popular month in spring to sell, came in joint second place. An average 68.8% of homes which were listed for sale in those two months went onto find a buyer. The data suggested that April was the third best month to put a home up for sale, with 68.7% of properties listed going on to find a buyer, followed by May (67.7%). Rightmove pointed out spring is known for typically being the peak season for buying and selling. Given that it takes an average seven months to find a buyer and complete an onward purchase, Rightmove said that many people aim to make progress on moves in the spring, so they can try to be in a new home before Christmas. While October came in last place, the analysis showed that an average 65.4% of homes listed in this month still go onto find a buyer on average, which is not far behind February's rate. Rightmove said this highlighted that the "best time to come to market is when home-movers are ready and motivated". The property platform's analysis also found that January was the quickest month to find a buyer. The data showed that, over the 10-year period analysed, homes listed for sale in January found a buyer in an average of 47 days. February was found to be the second quickest month, at an average of 48 days. Ma...
Borregaard’s operating revenues increased to NOK 1,833 million (NOK 1,744 million)2 in the 4th quarter of 2025. EBITDA1 was NOK 405 million (NOK 398 million). The result in BioMaterials increased, while BioSolutions and Fine Chemicals had lower results compared with the 4th quarter of 2024. In BioSolutions, high deliveries of biovanillin and sustained growth in sales to agriculture were more than ...
Borregaard’s operating revenues increased to NOK 1,833 million (NOK 1,744 million)2 in the 4th quarter of 2025. EBITDA1 was NOK 405 million (NOK 398 million). The result in BioMaterials increased, while BioSolutions and Fine Chemicals had lower results compared with the 4th quarter of 2024. In BioSolutions, high deliveries of biovanillin and sustained growth in sales to agriculture were more than offset by increased costs. For BioMaterials, higher sales prices and lower wood and energy costs, more than compensated for other cost increases. For Fine Chemicals, lower bioethanol sales prices were partly offset by a strong result for fine chemical intermediates. Net currency effects were slightly positive for the Group. In the 4th quarter of 2025, Borregaard has made a total impairment of NOK 245 million of its investments in the bio-based start-ups Alginor ASA, Kaffe Bueno ApS and Lignovations GmbH to reflect recent development in these companies. The impairment is recorded as part of financial items. Profit before tax was NOK -28 million (NOK 170 million). Earnings per share were NOK -0.81 (NOK 1.30). Excluding impairments of bio-based start-ups, earnings per share were NOK 1.64. Full year 2025 Operating revenues increased to NOK 7,713 million (NOK 7,617 million) in 2025. EBITDA1 was NOK 1,878 million (NOK 1,874 million), an all-time high result. BioSolutions and BioMaterials had improved results, while Fine Chemicals had a decrease compared with 2024. Profit before tax was NOK 864 million (NOK 1,079 million). Earnings per share were NOK 6.22 (NOK 8.25). Excluding impairments of bio-based start-ups, earnings per share were NOK 8.67. - We are pleased to report another all‑time high EBITDA1 in 2025, driven by strong momentum across our business segments, despite the sharp decline in bioethanol prices and higher costs, says CEO Tom Erik Foss-Jacobsen. Contacts: Director Investor Relations, Pål Espen Ramberg, +47 959 17 333 Director Communications, Tone Horvei Bredal, +47...
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz wuchs um +8% (kWk 1 , +8% USD), das operative Kernergebnis 1 verbesserte sich um +14% (kWk, +12% USD) Das Umsatzwachstum beruhte auf der weiterhin starken Performance der prioritären Marken wie Kisqali (+57% kWk), Kesimpta (+36% kWk), Pluvicto (+42% kWk), Scemblix (+85% kWk) und Cosentyx (+8% kWk) Die operative Kerngewinnmarge 1 err...
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz wuchs um +8% (kWk 1 , +8% USD), das operative Kernergebnis 1 verbesserte sich um +14% (kWk, +12% USD) Das Umsatzwachstum beruhte auf der weiterhin starken Performance der prioritären Marken wie Kisqali (+57% kWk), Kesimpta (+36% kWk), Pluvicto (+42% kWk), Scemblix (+85% kWk) und Cosentyx (+8% kWk) Die operative Kerngewinnmarge 1 erreichte 40,1%, +210 Basispunkte (kWk) Das operative Ergebnis verbesserte sich um +25% (kWk, +21% USD), der Reingewinn stieg um +19% (kWk, +17% USD) Der Kerngewinn pro Aktie 1 wuchs um +17% (kWk, +15% USD) auf USD 8,98 Der Free Cashflow1 belief sich infolge eines höheren Nettogeldflusses aus operativer Tätigkeit auf USD 17,6 Milliarden (+8% USD) Viertes Quartal Der Nettoumsatz ging aufgrund von Einbussen durch Generika und Anpassungen für Erlösminderungen in den USA um –1% (kWk, +1% USD) zurück; das operative Kernergebnis stieg um +1% (kWk, +1% USD) Die prioritären Marken behielten ihre starke Dynamik weiter bei, einschliesslich Kisqali (+44% kWk), Kesimpta (+27% kWk), Pluvicto (+70% kWk), Scemblix (+87% kWk) und Cosentyx (+11% kWk) Ausgewählte Meilensteine der Innovation im vierten Quartal: Zulassungsantrag für Remibrutinib beim häufigsten Subtyp chronisch induzierbarer Urtikaria (CINDU) bei der FDA eingereicht Positive Daten zu Pelabresib aus der Phase-III-Studie MANIFEST-2 nach 96 Wochen; Zulassungsantrag in der EU vorgesehen; Phase III in den USA geplant Zulassung der FDA für Itvisma als einzige Genersatztherapie für eine breite Patientenpopulation mit spinaler Muskelatrophie (SMA) Zulassung der Europäischen Kommission für Scemblix bei neu diagnostizierten Patienten mit Philadelphia-Chromosom-positiver chronischer myeloischer Leukämie (Ph+ CML) in der chronischen Phase Zulassungsantrag für Pluvicto bei PSMA-positivem metastasierendem hormonsensitivem Prostatakarzinom bei der FDA eingereicht Dividende, Prognose Für 2025 wird eine Dividende von CHF 3,70 pro Aktie – eine Erh...